SI
SI

 Biotech / Medical | Biotech Valuation


Previous 10 | Next 10 
To: Biomaven who wrote (38366)5/31/2012 8:20:32 PM
From: Arthur Radley   of 40323
 
nytimes.com 

A very encouraging article in the NYTimes----this might get a lot of attention at ASCO, starting tomorrow.

Relating to ASCO---a question! Since companies are required to submit their abstracts by February 1, would it be safe to assume that companies getting accepted for presentations, the submitted abstract only covers pre-February data, so during the presentation the actual data could be more extensive than what was filed. Is that correct? And if so, who do you think might have more important data being presented...your educated guess! (:>)

PS: The Red Soxs sucked last Friday, but we got a win for the Yankees--so trip was 50/50 if you consider that every Boston college student was at the Sam Adams brewery and had obtained every time slot for a tour. A real bummer!

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

From: Ian@SI5/31/2012 8:40:22 PM
2 Recommendations   of 40323
 
totally OT but interesting stuff...

Contact: J.D Harrington
jharring@nasa.gov
202-358-5241
NASA/Goddard Space Flight Center
NASA's Hubble shows Milky Way is destined for head-on collision
IMAGE: This illustration shows the collision paths of our Milky Way galaxy and the Andromeda galaxy. The galaxies are moving toward each other under the inexorable pull of gravity between them....


Click here for more information.
NASA astronomers announced Thursday they can now predict with certainty the next major cosmic event to affect our galaxy, sun, and solar system: the titanic collision of our Milky Way galaxy with the neighboring Andromeda galaxy.

The Milky Way is destined to get a major makeover during the encounter, which is predicted to happen four billion years from now. It is likely the sun will be flung into a new region of our galaxy, but our Earth and solar system are in no danger of being destroyed.

"Our findings are statistically consistent with a head-on collision between the Andromeda galaxy and our Milky Way galaxy," said Roeland van der Marel of the Space Telescope Science Institute (STScI) in Baltimore.

The solution came through painstaking NASA Hubble Space Telescope measurements of the motion of Andromeda, which also is known as M31. The galaxy is now 2.5 million light-years away, but it is inexorably falling toward the Milky Way under the mutual pull of gravity between the two galaxies and the invisible dark matter that surrounds them both.

"After nearly a century of speculation about the future destiny of Andromeda and our Milky Way, we at last have a clear picture of how events will unfold over the coming billions of years," said Sangmo Tony Sohn of STScI.

The scenario is like a baseball batter watching an oncoming fastball. Although Andromeda is approaching us more than two thousand times faster, it will take 4 billion years before the strike.

Computer simulations derived from Hubble's data show that it will take an additional two billion years after the encounter for the interacting galaxies to completely merge under the tug of gravity and reshape into a single elliptical galaxy similar to the kind commonly seen in the local universe.

Although the galaxies will plow into each other, stars inside each galaxy are so far apart that they will not collide with other stars during the encounter. However, the stars will be thrown into different orbits around the new galactic center. Simulations show that our solar system will probably be tossed much farther from the galactic core than it is today.

To make matters more complicated, M31's small companion, the Triangulum galaxy, M33, will join in the collision and perhaps later merge with the M31/Milky Way pair. There is a small chance that M33 will hit the Milky Way first.

The universe is expanding and accelerating, and collisions between galaxies in close proximity to each other still happen because they are bound by the gravity of the dark matter surrounding them. The Hubble Space Telescope's deep views of the universe show such encounters between galaxies were more common in the past when the universe was smaller.

A century ago astronomers did not realize that M31 was a separate galaxy far beyond the stars of the Milky Way. Edwin Hubble measured its vast distance by uncovering a variable star that served as a "milepost marker."

Hubble went on to discover the expanding universe where galaxies are rushing away from us, but it has long been known that M31 is moving toward the Milky Way at about 250,000 miles per hour. That is fast enough to travel from here to the moon in one hour. The measurement was made using the Doppler effect, which is a change in frequency and wavelength of waves produced by a moving source relative to an observer, to measure how starlight in the galaxy has been compressed by Andromeda's motion toward us.

Previously, it was unknown whether the far-future encounter will be a miss, glancing blow, or head-on smashup. This depends on M31's tangential motion. Until now, astronomers had not been able to measure M31's sideways motion in the sky, despite attempts dating back more than a century. The Hubble Space Telescope team, led by van der Marel, conducted extraordinarily precise observations of the sideways motion of M31 that remove any doubt that it is destined to collide and merge with the Milky Way.

"This was accomplished by repeatedly observing select regions of the galaxy over a five- to seven-year period," said Jay Anderson of STScI.

"In the worst-case-scenario simulation, M31 slams into the Milky Way head-on and the stars are all scattered into different orbits," said Gurtina Besla of Columbia University in New York, N.Y. "The stellar populations of both galaxies are jostled, and the Milky Way loses its flattened pancake shape with most of the stars on nearly circular orbits. The galaxies' cores merge, and the stars settle into randomized orbits to create an elliptical-shaped galaxy."

The space shuttle servicing missions to Hubble upgraded it with ever more-powerful cameras, which have given astronomers a long-enough time baseline to make the critical measurements needed to nail down M31's motion. The Hubble observations and the consequences of the merger are reported in three papers that will appear in an upcoming issue of the Astrophysical Journal.


###


For images, video, and more information about M31's collision with the Milky Way, visit:

nasa.gov 

hubblesite.org 

For more information about NASA's Hubble Space Telescope, visit:

nasa.gov 

Share Recommend | Keep | Reply | Mark as Last Read

To: Arthur Radley who wrote (38370)5/31/2012 8:49:30 PM
From: Biomaven   of 40323
 
Yes - the ASCO abstracts are often basically placeholders. For example, Ariad's abstract basically was little updated from their previous presentation, but the company says the actual data presented will have quite a bit more data and analysis. There are also some abstracts that are only released on the day of the presentation.

My guess is that the most significant new data presented at ASCO will be BMY's anti-PD-1, and we should also see some exciting data from PCYC. ARQL's overall survival numbers are of interest. JNJ will be presenting updated Zytiga data - if it's disappointing then MDVN should get a boost. ARRY's MEK inhibitor data is worth looking out for. EXEL data will be worth watching for as well.

I've never had much luck playing ASCO - very hard to know what news is already in the stock.

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Biomaven who wrote (38372)6/1/2012 11:24:18 AM
From: Chris08   of 40323
 
Given your biotech smarts, Peter, you would not be adverse to telling us what your major investments are? Or would you? No offense, I trust, in asking. :)

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Rocky9 who wrote (37852)6/1/2012 11:56:06 AM
From: Rocky9   of 40323
 
"OT - bond rates

I have been buying TIPs in my 401K for many years (even though I really don't believe in fixed income). I want a ladder for 20-30 years, and have bought some 30 year TIPs in relatively small quantities the last two years (which turned out to be great investments so far) after holding my nose since they were yielding "only" 2.25% real.

The 30 year TIP is now at .63% real as of today"

And today it is .36%. - see bloomberg.com 

"The once-a-year auction is on Thursday.

I can't do it this year. I have some 5 year TIPs coming due in April and may not reinvest those proceeds as planned."


I never invested in the ladder - too expensive - and I was very wrong (or at least have been so far). I have made the additional mistake of hedging the existing positions by buying TBT - luckily in relatively small quantities. Would have better off staying in cash. I wonder how many hedge funds have been caught short treasuries on this move. I bet a lot.

Oh well.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Chris08 who wrote (38373)6/1/2012 1:24:02 PM
From: Biomaven   of 40323
 
ARIA, PCYC, MDVN, VVUS, XNPT and a slew of smaller holdings.

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Biomaven who wrote (38375)6/1/2012 1:33:21 PM
From: Chris08   of 40323
 
Thanks very much.

Share Recommend | Keep | Reply | Mark as Last Read

To: Robert C. Jonson who wrote (38360)6/1/2012 9:04:09 PM
From: DewDiligence_on_SI   of 40323
 
Apropos to the vitamin-D video you cited:

finance.yahoo.com 

››Lunacalcipol is the first compound in a new class of vitamin D hormone analogs having a novel dual mechanism of action. Lunacalcipol is designed to be a strong activator of the vitamin D signaling pathway as well as a potent inhibitor of CYP24, the intracellular enzyme responsible for the catabolism of vitamin D hormones.‹‹

However, the development program has been dropped for commercial reasons:

››Lunacalcipol has shown great promise as a new treatment for secondary hyperparathyroidism without the calcemic side effects seen with existing vitamin D hormone therapies. But, unfortunately, recent restrictions in government reimbursement for drugs used in US dialysis patients make the continued development of lunacalcipol injection for that patient population financially unsustainable.‹‹

Share Recommend | Keep | Reply | Mark as Last Read

From: NP19866/2/2012 3:28:24 PM
   of 40323
 
Patients prefer Votrient to Sutent, according to PISCES study.

onclive.com 

Any thoughts on what implications this study has for not only Votrient uptake, but Astellas/AVEO's tivozanib, which has an even better tolerability profile?

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

From: NP19866/2/2012 3:28:24 PM
   of 40323
 
Patients prefer Votrient to Sutent, according to PISCES study.

onclive.com 

Any thoughts on what implications this study has for not only Votrient uptake, but Astellas/AVEO's tivozanib, which has an even better tolerability profile?

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.